Tafamidis ATTR denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for tafamidis attr are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Tafamidis (ATTR) as Duplicate Therapy

Aetna's duplicate-therapy denial for tafamidis means the plan has identified another therapy on your medication record that it considers to cover the same therapeutic purpose. For transthyretin amyloid cardiomyopathy (ATTR-CM) or transthyretin amyloid polyneuropathy (ATTR-PN), this denial most often arises when a different tafamidis formulation (there are two FDA-approved products with different strengths and formulations) is already on record, or — less commonly — when another ATTR stabilizer or polyneuropathy agent appears in your claims history.

This denial is strongly appealable when the prescriber documents the clinical distinction between the therapy on file and the prescribed tafamidis product. The two approved tafamidis products are not dose-equivalent and are not interchangeable without physician guidance; the FDA-approved prescribing information makes this explicit.

## Your Federal Appeal Rights

• Internal appeal: File within the timeframe on your Explanation of Benefits. Aetna must provide a written clinical rationale and the criteria applied to classify the therapy as duplicative.
• External review (ACA §2719): If the internal appeal is denied, you are entitled to independent external review from a reviewer unaffiliated with Aetna, generally within approximately four months of the final internal denial.
• ERISA §503: If your coverage is through an employer plan, ERISA's full-and-fair review rules apply, including the right to access all documents used in the determination.
• Expedited review: ATTR-CM carries significant cardiac risk. If delay poses a serious health threat, request expedited internal and external review simultaneously.

## What to Gather

1. Diagnosis confirmation: Cardiology or neurology records confirming your ATTR diagnosis (wild-type or variant) and the specific disease manifestation being treated. 2. Current medication list with context: Documentation of every ATTR-related therapy — including the product Aetna identified as duplicative — with dates, doses, and clinical rationale for each. 3. Distinction between tafamidis products: If the denial arose from the two tafamidis formulations being confused, your prescriber should document which product is prescribed and why it is the clinically appropriate choice, referencing the FDA-approved prescribing information. 4. Prescriber medical-necessity letter: Your cardiologist or neurologist should explain specifically why the prescribed therapy is not duplicative of whatever is already on your record, referencing the applicable ACC/AHA or neurology society guideline organization.

## Criteria-Mapping Structure

Obtain Aetna's clinical policy for tafamidis from their online clinical policy bulletin library. For each policy criterion, provide the corresponding chart documentation:

| Aetna Policy Criterion | Supporting Chart Documentation | |---|---| | [Criterion re: duplicative therapy] | [Prescriber note / medication history / lab date] |

A focused appeal letter from the treating cardiologist or neurologist that directly addresses the duplication claim — and distinguishes the prescribed product on clinical grounds — is the most effective format for overturning this denial.